PipelineReview.com2h
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
ZUG, Switzerland I 13, 2024 I MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating ...
PipelineReview.com55m
GIOSTAR Announces FDA Clearance of the IND for Starting PHASE-2 Clinical Trial for Developing Specific Stem Cell Therapy for Type II Diabetes.
SAN DIEGO, CA, USA I November 13, 2024 I Global Institute of Stem Cell Therapy and Research, Inc. known as GIOSTAR, a San Diego, California based Global organization at the forefront of stem cell ...
PipelineReview.com2h
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
SOUTH SAN FRANCISCO, CA, USA I 13, 2024 I TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create ...
PipelineReview.com17m
BioNTech to Acquire Biotheus to Boost Oncology Strategy
MAINZ, Germany I November 13, 2024 I BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a ...
PipelineReview.com47m
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
NEW YORK, NY, USA I November 13, 2024 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the ...
PipelineReview.com53m
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis
BETHESDA, MD & GAITHERSBURG, MD, USA I Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new ...
PipelineReview.com22h
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Collaboration will leverage Flare Therapeutics’ proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules ...
PipelineReview.com22h
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small ...